Skip to main content
Erschienen in: Indian Journal of Gastroenterology 2/2015

01.03.2015 | Original Article

Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy

verfasst von: Amarender Puri, Vaishali Bharadwaj, Sanjeev Sachdeva

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

There exists a two-way interaction between pregnancy and inflammatory bowel disease (IBD) wherein pregnancy may influence disease activity of the underlying IBD, and conversely, the status of the disease may have a direct effect on the outcome of pregnancy. Disease activity at the time of conception is considered the major determinant of the outcome of pregnancy. We evaluated the effect of disease extent on the outcome of pregnancy.

Methods

Forty-three females with ulcerative colitis and coexisting pregnancy were studied over a 4-year period from January 2010 to December 2013. Patients were divided into two groups on the basis of the extent of the disease determined prior to the onset of the pregnancy. Group I (n = 22) comprised of patients with pancolitis, whereas group II (n = 21) had disease limited to the splenic flexure. The following information regarding the outcome of the pregnancy or spontaneous abortion was obtained after informed consent: place of delivery (home or hospital), gestational length, mode of delivery, birth weight, congenital anomalies, drug treatment, compliance, and relapse during pregnancy if any. Data were compared between the two groups.

Results

Females with pancolitis had a mean age of 25.1 years with a disease duration of 4.2 years which was similar to patients in group II who had a mean age of 25.2 years and disease duration of 4 years (p = ns for both). Females in group I had a significantly higher rate of spontaneous abortions (n = 5 [23 %]), preterm delivery (n = 8 [36 %]), and low birth weight (n = 11 [50 %]) than patients in group II (0 [0 %], 1 [5 %], and 3 [14 %], respectively; p-values being <0.04, <0.02, and <0.02, respectively). Frequency of Caesarean section in group I and group II was 45 % and 19 %, respectively (p = 0.06). Frequency of disease relapse was higher in group I compared to group II (11 [50 %] vs. 3 [14 %], p < 0.02). None of the newborns in either group were detected to have any major congenital anomaly. On multivariate analysis using logistic regression, disease extent was the only independent predictor of adverse obstetrical outcomes.

Conclusions

Our study suggests that disease extent is a major determinant of the outcome of pregnancy in patients with ulcerative colitis. Patients with pancolitis may be at a higher risk of obstetric complications of ulcerative colitis vs. those with limited disease.
Literatur
1.
Zurück zum Zitat Heetun ZS, Byrnes C, Neary P, O’Morain C. Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:513–33.CrossRefPubMed Heetun ZS, Byrnes C, Neary P, O’Morain C. Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:513–33.CrossRefPubMed
2.
Zurück zum Zitat Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohn’s Colitis. 2011;5:317–23.CrossRef Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohn’s Colitis. 2011;5:317–23.CrossRef
3.
Zurück zum Zitat Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–9.CrossRefPubMed Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–9.CrossRefPubMed
4.
Zurück zum Zitat Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohn’s Colitis. 2011;5:234–8.CrossRef Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohn’s Colitis. 2011;5:234–8.CrossRef
5.
Zurück zum Zitat Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7:329–34.CrossRefPubMed Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7:329–34.CrossRefPubMed
6.
Zurück zum Zitat Birth rate, death rate, infant mortality rate and total fertility rate: India and States. National Commission on population. Govt. of India 2010. Birth rate, death rate, infant mortality rate and total fertility rate: India and States. National Commission on population. Govt. of India 2010.
7.
Zurück zum Zitat Puri AS. Epidemiology of ulcerative colitis in South Asia. Intest Res. 2013;11:250–5.CrossRef Puri AS. Epidemiology of ulcerative colitis in South Asia. Intest Res. 2013;11:250–5.CrossRef
8.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmed T, et al. Toward an integrated clinical molecular and serological classification of inflammatory bowel disease. Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.PubMed Silverberg MS, Satsangi J, Ahmed T, et al. Toward an integrated clinical molecular and serological classification of inflammatory bowel disease. Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.PubMed
9.
Zurück zum Zitat Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5 amino salicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRefPubMed Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5 amino salicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRefPubMed
10.
Zurück zum Zitat Mathai M, Jacob S, Karthikeyan NG. Birth weight standards for South Indian babies. Indian Pediatr. 1996;33:203–9.PubMed Mathai M, Jacob S, Karthikeyan NG. Birth weight standards for South Indian babies. Indian Pediatr. 1996;33:203–9.PubMed
11.
Zurück zum Zitat Kornfeld D, Cnattinguis S, Ekborn A. Pregnancy outcomes in women with inflammatory bowel disease—a population based cohort study. Am J Obstet Gynecol. 1997;177:942–6.CrossRefPubMed Kornfeld D, Cnattinguis S, Ekborn A. Pregnancy outcomes in women with inflammatory bowel disease—a population based cohort study. Am J Obstet Gynecol. 1997;177:942–6.CrossRefPubMed
12.
Zurück zum Zitat Hoie L, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–15.CrossRefPubMed Hoie L, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–15.CrossRefPubMed
13.
Zurück zum Zitat Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med. 1990;323:1228–33.CrossRefPubMed Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med. 1990;323:1228–33.CrossRefPubMed
14.
Zurück zum Zitat Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18:3839–48.CrossRefPubMedCentralPubMed Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18:3839–48.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.CrossRefPubMed Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.CrossRefPubMed
16.
Zurück zum Zitat Lin HC, Chiu CC, Chen SF, Lou HY, Chiu WT, Chen YH. Ulcerative colitis and pregnancy outcomes in an Asian population. Am J Gastroenterol. 2010;105:387–94.CrossRefPubMed Lin HC, Chiu CC, Chen SF, Lou HY, Chiu WT, Chen YH. Ulcerative colitis and pregnancy outcomes in an Asian population. Am J Gastroenterol. 2010;105:387–94.CrossRefPubMed
17.
Zurück zum Zitat Bharati P, Bandopadhyay M, Bhakta A, Chakraborty S. Prevalence and causes of low birth weight in India. Malays J Nutr. 2011;17:301–13.PubMed Bharati P, Bandopadhyay M, Bhakta A, Chakraborty S. Prevalence and causes of low birth weight in India. Malays J Nutr. 2011;17:301–13.PubMed
18.
Zurück zum Zitat Mahadevan U, Sandborn WJ, Li DK, Hakiman S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community based study from Northern California. Gastroenterology. 2007;133:1106–12.CrossRefPubMed Mahadevan U, Sandborn WJ, Li DK, Hakiman S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community based study from Northern California. Gastroenterology. 2007;133:1106–12.CrossRefPubMed
Metadaten
Titel
Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy
verfasst von
Amarender Puri
Vaishali Bharadwaj
Sanjeev Sachdeva
Publikationsdatum
01.03.2015
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 2/2015
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-015-0542-y

Weitere Artikel der Ausgabe 2/2015

Indian Journal of Gastroenterology 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.